Efficacy and safety of natalizumab extended interval dosing.
Sign Up to like & getrecommendations! Published in 2018 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2018.06.015
Abstract: OBJECTIVE It is postulated that extending the dosing interval of natalizumab (NTZ) from 4 to 5-8 weeks might decrease the risk of progressive multifocal leukoencephalopathy (PML). The aim of this study was to assess the… read more here.
Keywords: sid eid; efficacy safety; safety natalizumab; extended interval ... See more keywords